

Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human Papillomavirus Vaccination Series Initiation and Completion, 2008–2009. *Pediatrics*. 2011;128(5):830–839

An error occurred in the article by Dorell et al titled “Human Papillomavirus Vaccination Series Initiation and Completion, 2008–2009” published in the November 2011 issue of *Pediatrics* (2011;128[5]:830–839; originally published online October 7, 2011; doi:10.1542/peds.2011-0950). The error concerned rates of HPV vaccination completion among girls. On page 831, under the methods section, second paragraph, lines 19–26 read: “Because the third HPV vaccine dose is recommended to be administered 24 weeks after administration of the first dose, series completion was determined among girls who had received ≥ 1 HPV vaccine dose ≥ 24 weeks before the interview date.” However, on page 834, under Table 2 of the results section, the vaccination coverage estimates reported in the column ‘3 doses of HPV vaccine among those who initiated series’ were not reported among girls who had received ≥ 1 HPV vaccine dose ≥ 24 weeks before the interview date. They were reported among girls who received ≥ 1 HPV vaccine dose any time before the interview date and received the third HPV dose at least 6 months after the first HPV dose. The intention of the authors was to report completion rates among girls who received ≥ 1 HPV dose at least 6 months previous to the date of interview to reflect completion rates among girls who had sufficient time to complete the 3 dose HPV vaccination series. Corrected completion rates among girls who received ≥ 1 HPV vaccine dose at least 6 months before the interview are reported in the table. We found that HPV vaccination series completion estimates increased after limiting the analysis only to girls who had sufficient time to complete the series before the interview date. On page 833, under the results section, paragraph 3, lines 3–13 read: “In the multivariate analysis, completion of the 3-dose series was independently associated with age of 16 years, black non-Hispanic or Hispanic race/ethnicity, a household income of 133% to <322% of FPL, having an older mother, parental knowledge about HPV, and facility type where the adolescent received all of her vaccinations.” This should have read, “In the multivariate analysis, completion of the 3-dose series was independently associated with ages 14 or 16 years, Hispanic race/ethnicity, a household income of 133% to <322% of FPL, having an older mother, having SCHIP, parental knowledge about HPV, receipt of a provider recommendation, and facility type where the adolescent received all of her vaccinations.” On page 837, under the discussion section, paragraph 6, lines 27–29 read: “Black and Hispanic girls were less likely than white girls to complete the series.” This should have read, “Black, Hispanic, and Asian girls were less likely than white girls to complete the series; after controlling for other characteristics, these differences were statistically significant only for Hispanic girls.” We regret the error.

doi:10.1542/peds.2012-1013

TABLE 2 HPV Vaccination Coverage Among Girls 13 to 17 Years of Age, According to Sociodemographic Characteristics

Sociodemographic Characteristic	≥1 Dose of HPV Vaccine		≥3 doses of HPV Vaccine Among Those Who Initiated Series	
	Unadjusted Coverage Rate, % Estimate (95% CI)	Prevalence Ratio ^a	Unadjusted Coverage Rate, % Estimate (95% CI)	Prevalence Ratio ^a
Total	40.5 (39.2-41.9)	—	64.0 (61.5-66.5)	—
Year				
2008	37.0 (34.9-39.1) ^b	0.9 (0.8-1.0)	59.5 (55.4-63.4) ^b	0.9 (0.8-0.9)
2009	44.1 (42.3-46.0) ^c	Reference	67.6 (64.4-70.6) ^c	Reference
Age				
13 y	36.0 (33.2-38.9) ^c	Reference	56.9 (51.4-62.2) ^c	Referent
14 y	37.1 (34.2-40.1)	1.1 (1.0-1.2)	65.0 (59.8-69.9)	1.1 (1.0-1.2)
15 y	43.9 (40.8-47.1) ^b	1.2 (1.1-1.4)	58.3 (52.8-63.6)	1.0 (0.9-1.1)
16 y	42.9 (39.8-46.1) ^b	1.3 (1.1-1.5)	69.4 (63.5-74.8) ^b	1.2 (1.0-1.3)
17 y	42.3 (38.9-45.7) ^b	1.2 (1.1-1.4)	69.4 (63.9-74.4) ^b	1.1 (0.9-1.3)
Race				
White, non-Hispanic	39.3 (37.7-40.8) ^c	Reference	71.2 (68.3-73.9) ^c	Reference
Black, non-Hispanic	40.1 (36.1-44.2)	1.0 (0.9-1.1)	54.1 (46.7-61.3) ^b	0.9 (0.8-1.0)
Hispanic	44.5 (40.4-48.7) ^b	1.1 (1.0-1.2)	52.7 (46.1-59.1) ^b	0.9 (0.8-1.0)
American Indian/Alaskan Native	52.6 (41.4-63.5) ^b	1.2 (1.0-1.6)	54.2 (36.5-70.9)	1.0 (0.8-1.2)
Asian	41.1 (32.1-50.8)	1.0 (0.9-1.2)	52.4 (34.7-69.6) ^b	0.8 (0.6-1.2)
Other	40.9 (32.7-49.6)	0.9 (0.7-1.2)	59.4 (45.1-72.2)	0.9 (0.8-1.1)
Income level				
<133% of FPL	44.9 (41.6-48.3)	1.1 (0.9-1.2)	54.0 (48.3-59.6) ^b	1.0 (0.8-1.1)
133% to <322% of FPL	34.8 (32.5-37.2) ^b	0.9 (0.8-1.0)	59.9 (54.8-64.7) ^b	0.9 (0.8-1.0)
322% to <503% of FPL	39.6 (37.1-42.1) ^b	0.9 (0.9-1.0)	72.7 (68.5-76.5)	1.0 (0.9-1.1)
>503% of FPL	44.7 (41.8-47.6) ^c	Reference	71.8 (67.3-75.9) ^c	Reference
Mother's Education				
Less than high school	42.1 (37.7-46.6)	1.0 (0.9-1.2)	47.9 (40.4-55.4) ^b	0.9 (0.8-1.0)
High school	39.0 (35.9-42.2)	1.0 (0.9-1.1)	60.3 (54.3-66.0) ^b	0.9 (0.8-1.0)
More than high school, some college	39.9 (37.5-42.3)	1.0 (1.0-1.1)	65.2 (60.8-69.4) ^b	1.0 (0.9-1.1)
College graduate	41.7 (39.7-43.7) ^c	Reference	72.3 (69.2-75.2) ^c	Reference
Mother's marital status				
Married	39.3 (37.8-40.9) ^c	Reference	66.9 (64.1-69.5) ^c	Reference
Divorced/widowed/separated	41.8 (38.4-45.4)	1.1 (1.0-1.2)	60.5 (53.8-66.8) ^b	0.9 (0.9-1.0)
Never married	47.7 (42.2-53.2) ^b	1.2 (1.0-1.3)	46.0 (37.9-54.2) ^b	0.9 (0.8-1.0)
Mother's age				
≤34 y	45.6 (40.6-50.7) ^c	Reference	47.9 (39.8-56.2) ^c	Reference
35-44 y	39.2 (37.1-41.5) ^b	0.8 (0.8-0.9)	61.8 (57.6-65.8) ^b	1.1 (1.0-1.3)
≥45 y	40.9 (39.1-42.8)	0.8 (0.7-0.9)	69.3 (66.2-72.4) ^b	1.2 (1.0-1.3)
MSA				
Urban	43.0 (40.6-45.4) ^c	Reference	60.2 (56.3-64.0) ^c	Reference
Suburban	41.3 (39.2-43.5)	1.0 (0.9-1.1)	66.2 (62.1-70.1) ^b	1.0 (1.0-1.1)
Rural	32.8 (30.4-35.2) ^b	0.9 (0.9-1.0)	67.9 (63.4-72.1) ^b	1.1 (1.0-1.2)
Had 11- to 12-year preventive care visit				
Yes	48.8 (46.1-51.5) ^c	Reference	64.9 (60.7-68.8) ^c	Reference
No	31.2 (28.9-33.6) ^b	0.8 (0.7-0.9)	57.3 (52.2-62.2) ^b	1.0 (0.9-1.1)
HPV vaccine not licensed when 11 or 12 y of age ^d	41.9 (39.7-44.0) ^b	0.9 (0.8-1.0)	66.3 (62.4-69.9)	1.0 (0.9-1.1)
Insurance status				
Private	39.0 (37.4-40.7) ^c	Reference	68.3 (65.1-71.4) ^c	Reference
VFC-eligible, all others	47.3 (44.2-50.5) ^b	1.2 (1.1-1.3)	55.1 (50.0-60.2) ^b	1.0 (0.9-1.1)
VFC-eligible, uninsured only	23.7 (19.3-28.8) ^b	0.9 (0.7-1.1)	53.0 (41.9-63.9) ^b	1.0 (0.8-1.2)
SCHIP	52.4 (44.2-60.5) ^b	1.2 (1.0-1.5)	69.5 (57.8-79.2)	1.2 (1.1-1.4)
Military	35.1 (27.2-43.8)	0.8 (0.6-1.1)	68.9 (55.3-79.8)	1.0 (0.8-1.3)
Other	34.8 (21.8-50.6)	0.7 (0.4-1.2)	64.5 (36.6-85.1)	0.9 (0.6-1.3)
Know of HPV				
Yes	41.9 (40.6-43.4) ^c	Reference	66.2 (63.9-68.4) ^c	Reference
No	25.2 (18.8-32.9) ^b	1.0 (0.8-1.2)	24.4 (14.7-37.6) ^b	0.6 (0.4-0.9)
Heard of the HPV vaccine				
Yes	41.8 (40.3-43.2) ^c	Reference	66.3 (63.9-68.6) ^c	Reference
No	33.7 (29.2-38.5) ^b	1.0 (0.9-1.1)	50.5 (40.2-60.8) ^b	0.9 (0.8-1.0)

TABLE 2 Continued

Sociodemographic Characteristic	≥1 Dose of HPV Vaccine		≥3 doses of HPV Vaccine Among Those Who Initiated Series	
	Unadjusted Coverage Rate, % Estimate (95% CI)	Prevalence Ratio ^a	Unadjusted Coverage Rate, % Estimate (95% CI)	Prevalence Ratio ^a
Received provider recommendation for vaccine ^e				
Yes	58.3 (56.5-60.2) ^b	2.6 (2.4-2.9)	68.4 (65.8-70.9) ^b	1.1 (1.0-1.2)
No	20.7 (18.9-22.7) ^c	Reference	51.5 (45.6-57.3) ^c	Reference
Facility types for adolescent's vaccination providers				
All private facilities	44.7 (42.8-46.6) ^c	Reference	66.9 (63.6-70.0) ^c	Reference
All public facilities	26.5 (23.9-29.2) ^b	0.7 (0.6-0.8)	49.0 (43.0-55.1) ^b	0.9 (0.8-1.0)
All hospital facilities	44.8 (40.1-49.5)	1.0 (0.9-1.1)	61.7 (53.6-69.2)	0.9 (0.8-1.1)
All STD/school/teen clinics or other facilities	38.8 (31.0-47.2)	1.0 (0.8-1.2)	61.5 (44.8-75.8)	1.0 (0.8-1.2)
Mixed	42.4 (38.1-46.9)	1.0 (0.9-1.1)	68.0 (60.5-74.7)	1.0 (0.9-1.1)
Unknown	35.9 (29.7-42.7) ^b	0.9 (0.8-1.0)	56.8 (44.5-68.3)	0.9 (0.7-1.0)

STD indicates sexually transmitted disease.

^a Logistic regression models adjusted for survey year and state of residence.

^b $P \leq .05$.

^c Reference level.

^d Girls who were older than 12 years of age at the time of HPV vaccine licensure (June 8, 2006) and did not have the opportunity to receive HPV vaccine at an 11- to 12-year preventive visit.

^e Parents reported whether they had received a recommendation for their daughters to receive HPV vaccinations from a health care provider.

Kiang et al. Outbreak of Osteomyelitis/Septic Arthritis Caused by *Kingella kingae* Among Child Care Center Attendees. *Pediatrics*. 2005;116(2):e206–e213

An error occurred in this article by Kiang et al, titled “Outbreak of Osteomyelitis/Septic Arthritis Caused by *Kingella kingae* Among Child Care Center Attendees” published in the August 2005 issue of *Pediatrics* (2005;116[2]:e206–e213; originally published online July 15, 2005; doi:10.1542/peds.2004-2051). On page e207, under Intervention, lines 7–9, this reads: “a short prophylactic course of rifampin (**2 mg/kg/dose** up to 600 mg per dose for adults, twice daily for 2 days)”. This should have read: “a short prophylactic course of rifampin (**10 mg/kg/dose** up to 600 mg per dose for adults, twice daily for 2 days)”.

doi:10.1542/peds.2012-1263

Hayes et al. A Multicenter Collaborative Approach to Reducing Pediatric Codes Outside the ICU. *Pediatrics*. 2012;129(3):e785–e791

An error occurred in the article by Hayes et al, titled “A Multicenter Collaborative Approach to Reducing Pediatric Codes Outside the ICU” published in the March 2012 issue of *Pediatrics* (2012;129[3]:e785–e791; originally published online February 20, 2012; doi:10.1542/peds.2011-0227). Heather Richard was omitted from the author list. The complete list of authors should read as follows:

Leslie W. Hayes, MD, Children's Hospital of Alabama, UAB

Emily L. Dobyms, MD, FCCM, Children's Hospital Denver

Bruno DiGiovine, MD, MPH, Wayne State University

Ann-Marie Brown, MSN, CPNP-AC/PC, CCRN, Akron Children's Hospital

Sharon Jacobson, MBA, BSN, RN, CPHQ, Texas Children's Hospital

Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human Papillomavirus Vaccination Series Initiation and Completion, 2008-2009. *Pediatrics*. 2011; 128(5):830–839

Pediatrics 2012;130;166
DOI: 10.1542/peds.2012-1013

Updated Information & Services	including high resolution figures, can be found at: http://pediatrics.aappublications.org/content/130/1/166
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Infectious Disease http://www.aappublications.org/cgi/collection/infectious_diseases_sub Vaccine/Immunization http://www.aappublications.org/cgi/collection/vaccine_immunization_sub
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.aappublications.org/site/misc/Permissions.xhtml
Reprints	Information about ordering reprints can be found online: http://www.aappublications.org/site/misc/reprints.xhtml

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human Papillomavirus Vaccination Series Initiation and Completion, 2008-2009. *Pediatrics*. 2011; 128(5):830–839

Pediatrics 2012;130;166

DOI: 10.1542/peds.2012-1013

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/130/1/166>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2012 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

